Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 16Breast Neoplasms 10Brain Neoplasms 7Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma 4Urinary Bladder Neoplasms 3Spinal Cord Neoplasms 3Multiple Myeloma 2Lymphoma, B-Cell 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Thoracic Neoplasms 1Thoracic Diseases 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinal Diseases 1Solid Tumor, Adult 1Sinusitis 1Sarcoma 1

Interventions

Cyclophosphamide 118Peripheral Blood Stem Cell Transplantation 67Filgrastim 60Etoposide 60Rituximab 54fludarabine phosphate 50Vincristine 46Radiotherapy 46Methotrexate 46Cytarabine 44Doxorubicin 40Cyclosporine 35Mycophenolic Acid 33Busulfan 33Prednisone 32Whole-Body Irradiation 31Tacrolimus 28Antilymphocyte Serum 28Melphalan 27Dexamethasone 26Methylprednisolone 22Leucovorin 19Carmustine 18Granulocyte Colony-Stimulating Factor 17Calcium Dobesilate 16Ifosfamide 15Psychiatric Rehabilitation 13Cord Blood Stem Cell Transplantation 13sargramostim 12merphos 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Burkitt Lymphoma × Magnetic Resonance Imaging × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡